Volume Alert - NVO 44.29 Novo Nordisk A/S $NVO Hit
Post# of 94143
Posted On: 11/12/2014 3:02:07 PM
Volume Alert - NVO 44.29 Novo Nordisk A/S $NVO Hit a high today of 44.36 Closing the day 10:30 at 44.29 -0.04 -0.09% With a day low of 43.98 and a total volume of 765,567.
NVO Recent Posts: http://investorshangout.com/Novo-Nordisk-AS-NVO-52132/
NVO Novo Nordisk A/S Recent Headline News
Novo Nordisk takes diabetes screening and education to the streets of Philadelphia with the Diabetes Living Room
PR Newswire - Wed Nov 12, 7:00AM CST
Novo Nordisk today announced the debut of the Diabetes Living Room, a community-based diabetes awareness, screening, and education program that will take place in Philadelphia on November 12 to 14, 2014. In Philadelphia, 655,818 people are living with diabetes and Novo Nordisk has teamed up with Independence Blue Cross of Philadelphia, the American Diabetes Association (ADA) and the Philadelphia Union soccer team to educate the city of Philadelphia about the importance of proper education and timely screening for diabetes.
NVO: 44.18 (-0.15)
Novo-Nordisk Is A Great Healthcare Stock That Isn't Overstretched
Abba's Aces - at Seeking Alpha - Wed Nov 12, 6:32AM CST
NVO: 44.18 (-0.15)
PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Report
M2 - Wed Nov 12, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kjfp3/pharmapoint) has announced the addition of the "PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Several pharmaceutical companies, including Biogen Idec, Novo Nordisk, Bayer, Baxter and CSL Behring, will be launching long-acting rFVIII and rFIX therapies that aim to address this unmet need by providing increased protein half-life that potentially extends the time between prophylactic doses. The emergence of these new products, beginning in 2014 in the US and 2015 in the 5EU, will have a drastic effect on the hemophilia A and B treatment landscapes in the 7MM as patients adopt these premium-priced products. This sea change will be lead by Biogen Idec's Alprolix and Eloctate, which launched in the US in March and June 2014. Key Questions Answered - How will the launch of long-acting rFVIII and rFIX replacement products affect the hemophilia A and B recombinant treatment landscape? How will Biogen Idec's pricing strategy impact market growth? - How will launch timing of the long-acting products affect patient adoption over the forecast period? - The unmet needs of hemophilia A and B patients in the US and 5EU are relatively low. What unmet needs will remain after the launch of the long-acting factors? - How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU? - The level of unmet needs for hemophilia patients in the developing markets of Argentina and China are higher compared to the established markets. Will the launch of long-acting products affect these markets? What additional opportunity will remain during the forecast period? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Baxter - Biogen Idec - Novo Nordisk - CSL Behring - Bayer - Pfizer For more information visit http://www.researchandmarkets.com/research/5k...harmapoint
BIIB: 320.47 (-4.12), NVO: 44.18 (-0.15)
Novo Nordisk Set to Possibly Pullback After Yesterday's Rally of 2.38%
Comtex SmarTrend(R) - Tue Nov 11, 4:23PM CST
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $43.78 to a high of $44.36. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $44.21 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVO: 44.18 (-0.15)
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk
PR Newswire - Tue Nov 11, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:
IPXL: 29.44 (+0.32), NVO: 44.18 (-0.15), AZN: 74.20 (unch), SLXP: 95.93 (-3.08), NVS: 92.55 (-0.22)
Novo Nordisk A/S: Novo Nordisk A/S - Share repurchase programme
GlobeNewswire - Mon Nov 10, 7:44AM CST
On 30 October 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.
NVO: 44.18 (-0.15)
MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST
NVO: 44.18 (-0.15), PFE: 30.40 (+0.08), LLY: 67.54 (-0.31), MNKD: 6.03 (-0.01), SNY: 46.35 (-0.79)
Dividend Contenders, Future Champions Or Future Failures: Part 6
Stan Stafford - at Seeking Alpha - Fri Nov 07, 5:13PM CST
PRGO: 154.65 (-0.79), NVO: 44.18 (-0.15), CAH: 80.16 (+0.56), TEVA: 58.30 (+0.11)
Novo Nordisk A/S - Trading in Novo Nordisk shares by board members, executives and associated persons on 31 October 2014
GlobeNewswire - Thu Nov 06, 8:46AM CST
In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.
NVO: 44.18 (-0.15)
Human Insulin Market worth $42 Billion by 2019 - Prominent Players are Novo Nordisk (Denmark), Eli Lilly (U.S) & Biocon (India)
M2 - Thu Nov 06, 6:06AM CST
Human insulin for therapeutic use is a non-glycosylated, disulphide-bonded heterodimer of 51 amino acids and has a key role in regulating glucose metabolism. It is an important drug for treating diabetes mellitus, mainly type 1 diabetes. Both biologics (Branded drugs), and biosimilars (Generic version of branded drugs) have been covered in this study.
NVO: 44.18 (-0.15), LLY: 67.54 (-0.31)
Novo Nordisk Re-Launches Cornerstones4Care® with Customized Diabetes Patient Support Program
PR Newswire - Wed Nov 05, 7:07AM CST
Novo Nordisk, a world leader in diabetes care, today announced the re-launch of Cornerstones4Care®, an award-winning online patient support platform for people living with diabetes. The diabetes support platform has been enhanced to customize the patient experience with educational resources for people at each phase of their diabetes journey while focusing on the four cornerstones of diabetes care: healthy eating, being active, medicine, and tracking.
NVO: 44.18 (-0.15)
China Recombinant & Modern Insulin Market 2014-2018
M2 - Wed Nov 05, 5:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/kld485/insulin_market_in) has announced the addition of the "Insulin Market in China 2014-2018" report to their offering. The Insulin market in China to grow at a CAGR of 15.57% over the period 2013-2018 One key trend witnessed in the market is an increase in strategic alliances among vendors. There has been a significant increase in the number of corporate agreements between global and regional vendors, which increases the competition in the market. According to the report, an increase in the number of patients suffering from diabetes and diabetes-related diseases is one of the major growth factors in this market. Over the last few years, almost 92 million people have been diagnosed with diabetes in China, and this is expected to increase to 435 million by 2030. Further, the report states that one of the main challenges in the market is the high cost of insulin. The average price of human insulin developed by the global vendors in China is higher than that of the human insulin developed by the regional or local vendors in the country. To calculate the market size, the report considers revenue generated through the sales of various second and third generation insulin products. Key Vendors - Eli Lilly - Novo Nordisk - Sanofi - Tonghua Dongbao Pharmaceutical Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type - Market Assessment of Top Drugs - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/kl..._market_in
NVO: 44.18 (-0.15), LLY: 67.54 (-0.31)
Media Release - Top 100 Employer
CNW Group - Tue Nov 04, 4:43PM CST
Novo Nordisk Canada is pleased to be included in the "Canada's Top 100 Employers" listing for 2015 announced in a special magazine co-published in the national edition of The Globe and Mail this morning.
NVO: 44.18 (-0.15)
10 Dividend Growth Stocks For November 2014
FerdiS - Seeking Alpha - Tue Nov 04, 2:41PM CST
One of my goals for 2014 is to balance DivGro's holdings across all 10 sectors in my watch list . Rather than targeting an equal number of holdings in each sector, I prefer to target a distribution proportional to the number of candidates in each...
CMS: 32.50 (-0.76), NVO: 44.18 (-0.15), ALB: 61.62 (-0.42), QCOM: 70.19 (+0.55), HMN: 31.51 (+0.22), CPA: 112.87 (-0.94), HP: 85.13 (-0.88), GPS: 39.22 (+0.40), VZ: 50.95 (+0.34), CCE: 42.84 (+0.29)
Digesting Sanofi's Two Pieces Of News- Lantus' Challenging Outlook And The CEO Dismissal
Zejia Yao - Seeking Alpha - Tue Nov 04, 9:49AM CST
Sanofi (NYSE: SNY ) released two pieces of bad news in two consecutive days. One is the flat outlook of the diabetes business due to one of its largest selling products, Lantus facing competitive pricing. The other piece of news, which came a day...
NVO: 44.18 (-0.15), MRK: 59.20 (-0.17), LLY: 67.54 (-0.31), SNY: 46.35 (-0.79)
Novo Nordisk A/S's (NVO) CEO Lars Sørensen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 8:41PM CST
NVO: 44.18 (-0.15)
Global Peptide Therapeutics Market 2014-2018: Key Vendors are AstraZeneca, Eli Lilly, Novo Nordisk and Sanofi
PR Newswire - Mon Nov 03, 12:14PM CST
Research and Markets has announced the addition of the "Global Peptide Therapeutics Market 2014-2018" report to their offering.
NVO: 44.18 (-0.15), LLY: 67.54 (-0.31)
Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:10AM CST
Novo Nordisk's (NVO) reported third-quarter 2014 earnings of 44 cents per American Depository Receipt (ADR), higher than the year-ago earnings of 42 cents.
AGN: 195.91 (+0.57), NVO: 44.18 (-0.15), GILD: 107.16 (-0.85), ABBV: 63.76 (-0.09)
City of Houston and Novo Nordisk Partner to Lead Fight Against Urban Diabetes Epidemic
PR Newswire - Mon Nov 03, 10:00AM CST
The City of Houston and Novo Nordisk today announced an innovative partnership to fight the urban diabetes epidemic. Houston is the third city globally and the first in the United States to join the Cities Changing Diabetes program, which was initiated earlier in 2014 by Novo Nordisk. The first two cities are Mexico City and Copenhagen.
NVO: 44.18 (-0.15)
3 Dividend Stocks Better Than Pfizer, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 01, 10:17AM CDT
Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's...
NVO: 44.18 (-0.15), PFE: 30.40 (+0.08), AMGN: 162.13 (-0.29), NVS: 92.55 (-0.22)
NVO Recent Posts: http://investorshangout.com/Novo-Nordisk-AS-NVO-52132/
NVO Novo Nordisk A/S Recent Headline News
Novo Nordisk takes diabetes screening and education to the streets of Philadelphia with the Diabetes Living Room
PR Newswire - Wed Nov 12, 7:00AM CST
Novo Nordisk today announced the debut of the Diabetes Living Room, a community-based diabetes awareness, screening, and education program that will take place in Philadelphia on November 12 to 14, 2014. In Philadelphia, 655,818 people are living with diabetes and Novo Nordisk has teamed up with Independence Blue Cross of Philadelphia, the American Diabetes Association (ADA) and the Philadelphia Union soccer team to educate the city of Philadelphia about the importance of proper education and timely screening for diabetes.
NVO: 44.18 (-0.15)
Novo-Nordisk Is A Great Healthcare Stock That Isn't Overstretched
Abba's Aces - at Seeking Alpha - Wed Nov 12, 6:32AM CST
NVO: 44.18 (-0.15)
PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Report
M2 - Wed Nov 12, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kjfp3/pharmapoint) has announced the addition of the "PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Several pharmaceutical companies, including Biogen Idec, Novo Nordisk, Bayer, Baxter and CSL Behring, will be launching long-acting rFVIII and rFIX therapies that aim to address this unmet need by providing increased protein half-life that potentially extends the time between prophylactic doses. The emergence of these new products, beginning in 2014 in the US and 2015 in the 5EU, will have a drastic effect on the hemophilia A and B treatment landscapes in the 7MM as patients adopt these premium-priced products. This sea change will be lead by Biogen Idec's Alprolix and Eloctate, which launched in the US in March and June 2014. Key Questions Answered - How will the launch of long-acting rFVIII and rFIX replacement products affect the hemophilia A and B recombinant treatment landscape? How will Biogen Idec's pricing strategy impact market growth? - How will launch timing of the long-acting products affect patient adoption over the forecast period? - The unmet needs of hemophilia A and B patients in the US and 5EU are relatively low. What unmet needs will remain after the launch of the long-acting factors? - How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU? - The level of unmet needs for hemophilia patients in the developing markets of Argentina and China are higher compared to the established markets. Will the launch of long-acting products affect these markets? What additional opportunity will remain during the forecast period? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Baxter - Biogen Idec - Novo Nordisk - CSL Behring - Bayer - Pfizer For more information visit http://www.researchandmarkets.com/research/5k...harmapoint
BIIB: 320.47 (-4.12), NVO: 44.18 (-0.15)
Novo Nordisk Set to Possibly Pullback After Yesterday's Rally of 2.38%
Comtex SmarTrend(R) - Tue Nov 11, 4:23PM CST
Novo Nordisk (NYSE:NVO) traded in a range yesterday that spanned from a low of $43.78 to a high of $44.36. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $44.21 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
NVO: 44.18 (-0.15)
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk
PR Newswire - Tue Nov 11, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:
IPXL: 29.44 (+0.32), NVO: 44.18 (-0.15), AZN: 74.20 (unch), SLXP: 95.93 (-3.08), NVS: 92.55 (-0.22)
Novo Nordisk A/S: Novo Nordisk A/S - Share repurchase programme
GlobeNewswire - Mon Nov 10, 7:44AM CST
On 30 October 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January 2014.
NVO: 44.18 (-0.15)
MannKind Is On The Mend
Nicholas Kitonyi - at Seeking Alpha - Fri Nov 07, 6:07PM CST
NVO: 44.18 (-0.15), PFE: 30.40 (+0.08), LLY: 67.54 (-0.31), MNKD: 6.03 (-0.01), SNY: 46.35 (-0.79)
Dividend Contenders, Future Champions Or Future Failures: Part 6
Stan Stafford - at Seeking Alpha - Fri Nov 07, 5:13PM CST
PRGO: 154.65 (-0.79), NVO: 44.18 (-0.15), CAH: 80.16 (+0.56), TEVA: 58.30 (+0.11)
Novo Nordisk A/S - Trading in Novo Nordisk shares by board members, executives and associated persons on 31 October 2014
GlobeNewswire - Thu Nov 06, 8:46AM CST
In accordance with Section 28a of the Danish Securities Trading Act, the company's board members and executives have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company's board members, executives and their associated persons as reported by those persons to Novo Nordisk.
NVO: 44.18 (-0.15)
Human Insulin Market worth $42 Billion by 2019 - Prominent Players are Novo Nordisk (Denmark), Eli Lilly (U.S) & Biocon (India)
M2 - Thu Nov 06, 6:06AM CST
Human insulin for therapeutic use is a non-glycosylated, disulphide-bonded heterodimer of 51 amino acids and has a key role in regulating glucose metabolism. It is an important drug for treating diabetes mellitus, mainly type 1 diabetes. Both biologics (Branded drugs), and biosimilars (Generic version of branded drugs) have been covered in this study.
NVO: 44.18 (-0.15), LLY: 67.54 (-0.31)
Novo Nordisk Re-Launches Cornerstones4Care® with Customized Diabetes Patient Support Program
PR Newswire - Wed Nov 05, 7:07AM CST
Novo Nordisk, a world leader in diabetes care, today announced the re-launch of Cornerstones4Care®, an award-winning online patient support platform for people living with diabetes. The diabetes support platform has been enhanced to customize the patient experience with educational resources for people at each phase of their diabetes journey while focusing on the four cornerstones of diabetes care: healthy eating, being active, medicine, and tracking.
NVO: 44.18 (-0.15)
China Recombinant & Modern Insulin Market 2014-2018
M2 - Wed Nov 05, 5:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/kld485/insulin_market_in) has announced the addition of the "Insulin Market in China 2014-2018" report to their offering. The Insulin market in China to grow at a CAGR of 15.57% over the period 2013-2018 One key trend witnessed in the market is an increase in strategic alliances among vendors. There has been a significant increase in the number of corporate agreements between global and regional vendors, which increases the competition in the market. According to the report, an increase in the number of patients suffering from diabetes and diabetes-related diseases is one of the major growth factors in this market. Over the last few years, almost 92 million people have been diagnosed with diabetes in China, and this is expected to increase to 435 million by 2030. Further, the report states that one of the main challenges in the market is the high cost of insulin. The average price of human insulin developed by the global vendors in China is higher than that of the human insulin developed by the regional or local vendors in the country. To calculate the market size, the report considers revenue generated through the sales of various second and third generation insulin products. Key Vendors - Eli Lilly - Novo Nordisk - Sanofi - Tonghua Dongbao Pharmaceutical Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Rate of Incidence and Prevalence - Market Segmentation by Type - Market Assessment of Top Drugs - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/kl..._market_in
NVO: 44.18 (-0.15), LLY: 67.54 (-0.31)
Media Release - Top 100 Employer
CNW Group - Tue Nov 04, 4:43PM CST
Novo Nordisk Canada is pleased to be included in the "Canada's Top 100 Employers" listing for 2015 announced in a special magazine co-published in the national edition of The Globe and Mail this morning.
NVO: 44.18 (-0.15)
10 Dividend Growth Stocks For November 2014
FerdiS - Seeking Alpha - Tue Nov 04, 2:41PM CST
One of my goals for 2014 is to balance DivGro's holdings across all 10 sectors in my watch list . Rather than targeting an equal number of holdings in each sector, I prefer to target a distribution proportional to the number of candidates in each...
CMS: 32.50 (-0.76), NVO: 44.18 (-0.15), ALB: 61.62 (-0.42), QCOM: 70.19 (+0.55), HMN: 31.51 (+0.22), CPA: 112.87 (-0.94), HP: 85.13 (-0.88), GPS: 39.22 (+0.40), VZ: 50.95 (+0.34), CCE: 42.84 (+0.29)
Digesting Sanofi's Two Pieces Of News- Lantus' Challenging Outlook And The CEO Dismissal
Zejia Yao - Seeking Alpha - Tue Nov 04, 9:49AM CST
Sanofi (NYSE: SNY ) released two pieces of bad news in two consecutive days. One is the flat outlook of the diabetes business due to one of its largest selling products, Lantus facing competitive pricing. The other piece of news, which came a day...
NVO: 44.18 (-0.15), MRK: 59.20 (-0.17), LLY: 67.54 (-0.31), SNY: 46.35 (-0.79)
Novo Nordisk A/S's (NVO) CEO Lars Sørensen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 03, 8:41PM CST
NVO: 44.18 (-0.15)
Global Peptide Therapeutics Market 2014-2018: Key Vendors are AstraZeneca, Eli Lilly, Novo Nordisk and Sanofi
PR Newswire - Mon Nov 03, 12:14PM CST
Research and Markets has announced the addition of the "Global Peptide Therapeutics Market 2014-2018" report to their offering.
NVO: 44.18 (-0.15), LLY: 67.54 (-0.31)
Novo Nordisk's Earnings Rise in Q3, 2014 Outlook Narrowed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 10:10AM CST
Novo Nordisk's (NVO) reported third-quarter 2014 earnings of 44 cents per American Depository Receipt (ADR), higher than the year-ago earnings of 42 cents.
AGN: 195.91 (+0.57), NVO: 44.18 (-0.15), GILD: 107.16 (-0.85), ABBV: 63.76 (-0.09)
City of Houston and Novo Nordisk Partner to Lead Fight Against Urban Diabetes Epidemic
PR Newswire - Mon Nov 03, 10:00AM CST
The City of Houston and Novo Nordisk today announced an innovative partnership to fight the urban diabetes epidemic. Houston is the third city globally and the first in the United States to join the Cities Changing Diabetes program, which was initiated earlier in 2014 by Novo Nordisk. The first two cities are Mexico City and Copenhagen.
NVO: 44.18 (-0.15)
3 Dividend Stocks Better Than Pfizer, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 01, 10:17AM CDT
Pfizer reported third-quarter earnings this week that were generally underwhelming. The drugmaker announced that its sales sagged 2.2% to $12.36 billion and its adjusted EPS fell similarly by 2% year over year in the quarter. Pfizer's...
NVO: 44.18 (-0.15), PFE: 30.40 (+0.08), AMGN: 162.13 (-0.29), NVS: 92.55 (-0.22)
(0)
(0)Scroll down for more posts ▼